HUTCHMED (China) Ltd (STU:H7T1)
€ 16.1 0.5 (3.21%) Market Cap: 2.75 Bil Enterprise Value: 2.08 Bil PE Ratio: 0 PB Ratio: 4.11 GF Score: 64/100

Half Year 2020 Hutchison China MediTech Ltd Earnings Call Transcript

Jul 30, 2020 / 12:00PM GMT
Release Date Price: €22.6
Christian Lawrence Hogg;China;Limited;Former CEO;Executive Director
HUTCHMED

()-&

Okay. This is Christian Hogg, CEO of Chi-Med. Welcome to the interim 2020 first half results. On the line today, we have myself. I have Dr. Wei-Guo Su, our Chief Scientific Officer; and I have Johnny Cheng, our Chief Financial Officer.

So if we go straight to the presentation. What I'm going to do is spend maybe 25, 30 minutes on the presentation and then leave half an hour for questions at the end.

So starting on Page 3. The overall strategy of the business remains very well established, but I think Page 3 sums it up very clearly, even more so than perhaps in the last couple of years. We are obviously trying to build a global science-focused biopharmaceutical company from our established base in China. But really, the 2 key focus areas are realizing the global potential of our novel oncology assets, so building out our global team to maximize the potential of those programs. And then the second area is really building out our fully

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot